Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Nicholas K Mollanazar"'
Autor:
Gil Yosipovitch, MD, Brian S. Kim, MD, Shawn G. Kwatra, MD, Nicholas K. Mollanazar, MD, Sonja Ständer, MD, Takahiro Satoh, MD, PhD, Pedro Mendes-Bastos, MD, Tsen-Fang Tsai, MD, Elizabeth Laws, PhD, Michael C. Nivens, PhD, Jennifer Maloney, MD, Genming Shi, PhD, Ashish Bansal, MD, MBA, Ariane Dubost-Brama, MD
Publikováno v:
JAAD International, Vol 16, Iss , Pp 163-174 (2024)
Background: Phase 3 PRIME/PRIME2 trials independently demonstrated efficacy and an acceptable safety profile of dupilumab adults with moderate-to-severe prurigo nodularis. Objective: To obtain a more precise estimate of onset and magnitude of treatme
Externí odkaz:
https://doaj.org/article/711afba8cadd4d1c95210d2031b7c4d3
Autor:
Charissa N. Obeng-Nyarko, MS, Kevin Puerta Durango, BS, BA, Shanelle Jackson, BS, Olaf Rodriguez, MD, Nicholas K. Mollanazar, MD, MBA
Publikováno v:
JAAD Case Reports, Vol 50, Iss , Pp 9-11 (2024)
Externí odkaz:
https://doaj.org/article/1956dc35d7264b348f93c75207f9c93a
Autor:
Corbett T. Berry, MD, PhD, Katarina G. Berry, MS, RD, LDN, James Abbott, MD, Angela J. Jiang, MD, Lukas Ronner, MD, MSc, Nicholas K. Mollanazar, MD, Robin Canada, MD, Douglas J. Pugliese, MD, MPH, Temitayo A. Ogunleye, MD
Publikováno v:
JAAD Case Reports, Vol 22, Iss , Pp 27-30 (2022)
Externí odkaz:
https://doaj.org/article/9c095db365a247c991d081acb0fcd979
Autor:
Margaret Wat, Nicholas K. Mollanazar, Christoph T. Ellebrecht, Amy Forrestel, Rosalie Elenitsas, Emily Y. Chu
Publikováno v:
Journal of Cutaneous Pathology. 49:978-987
Programmed cell death protein (PD-1) and programmed death-ligand 1 (PD-L1) inhibition checkpoint blockade leads to various cutaneous adverse reactions, including bullous pemphigoid and lichen-planus-like reactions. However, lichen planus pemphigoides
Autor:
Lisa L. Zhai, Kevin T. Savage, Connie C. Qiu, Annie Jin, Rodrigo Valdes-Rodriguez, Nicholas K. Mollanazar
Publikováno v:
Medicines, Vol 6, Iss 3, p 72 (2019)
Background: Chronic pruritus is defined as itch lasting for greater than six weeks. Pruritus is a burdensome manifestation of several internal and external disease states with a significant impact on quality of life. Dupilumab has shown promise in tr
Externí odkaz:
https://doaj.org/article/ea2bdc5f05e44dd894f71fbd5ff52af2
Publikováno v:
Dermatology and Therapy
There is currently no standardized algorithm for the treatment of chronic pruritus (CP), or itch lasting more than 6 weeks, in adults aged ≥ 65 years. The antiepileptic agents gabapentin and pregabalin, however, are gaining popularity in the dermat
Publikováno v:
Journal of Cutaneous Pathology. 47:781-784
Autor:
Bobak T Pousti, Lisa L Zhai, Annie Jin, Nicholas K Mollanazar, Candrice R Heath, Kevin T. Savage, Lindsay Sklovar
Publikováno v:
Cutis. 107(4)
Autor:
Ellen J. Kim, Christina A Del Guzzo, Bobak T. Pousti, Nicholas K. Mollanazar, Carmela C. Vittorio, Alain H. Rook, Paul Haun, Kevin T. Savage, Neha Jariwala
Publikováno v:
Cutis. 106
Cutaneous T-cell lymphoma (CTCL) represents a diagnostic challenge because of its large symptomatic overlap with other common skin conditions such as atopic dermatitis (AD) and psoriasis. Dupilumab has offered promising results in AD treatment; howev
Autor:
Nina A Ran, Junqian Zhang, Krisda H. Chaiyachati, John T. Howell, Sara Samimi, Susan C. Day, C. William Hanson, Colleen P. Mallozzi, Nicholas K. Mollanazar
Publikováno v:
Journal of the American Academy of Dermatology